HDAC6 Antibodies

Structure of HDAC6

HDAC6 is a cytoplasmic protein with a molecular weight of approximately 131 kDa. This enzyme is composed of 1,215 amino acids, and its molecular weight is highly conserved among different species, mainly due to the stable sequence of its functional domain.

HDAC6 contains two tandem deacetylase catalytic domains (DD1 and DD2), which can bind to ubiquitin chains through zinc finger domains and thereby recognize and modify substrates. Its tertiary structure forms special hydrophobic channels that can specifically bind to non-histone substrates such as tubulin and heat shock protein 90 (Hsp90). Its unique structural features enable it to be widely involved in processes such as autophagy, stress response and immune regulation of cells.

Fig. 1 Functional domains of HDAC6.¹

Key structural properties of HDAC6:

• Tandem dual catalytic domains (DD1 and DD2)
• Cytoplasmic localized zinc finger domain (ZnF-UBP)
• Highly conservative substrate recognition channels

Functions of HDAC6

The main function of HDAC6 is to regulate the deacetylation modification of cytoplasmic proteins and participate in various pathophysiological processes.

The substrate specificity of HDAC6 and its synergistic effect with the ubiquitin-proteasome system endow it with unique dual regulatory characteristics in the regulation of intracellular homeostasis.

Applications of HDAC6 and HDAC6 Antibody in Literature

1. LoPresti, Patrizia. "HDAC6 in diseases of cognition and of neurons." Cells 10.1 (2020): 12. https://doi.org/10.3390/cells10010012

The article indicates that HDAC6 mainly affects intracellular transport, synaptic transmission and protein aggregation in neurons by regulating non-histone acetylation. Under pathological conditions, its nuclear translocation aggravates transcriptional abnormalities and synaptic damage, and early functional disorders may drive the neurodegenerative process. Research on selective inhibitors provides directions for intervention.

2. Ranjbarvaziri, Sara, et al. "Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice." nature communications 15.1 (2024): 1352. https://doi.org/10.1038/s41467-024-45440-7

Research has found that inhibiting HDAC6 can effectively reverse the symptoms of heart failure in HFpEF mice, and its effect is comparable to that of SGLT2 inhibitors and enhances when used in combination. The mechanism involves improving myocardial fibrosis, hypertrophy and mitochondrial function. HDAC6 is a potential therapeutic target for HFpEF.

3. Jo, Hyein, Kyeonghee Shim, and Dooil Jeoung. "Targeting HDAC6 to overcome autophagy-promoted anti-cancer drug resistance." International Journal of Molecular Sciences 23.17 (2022): 9592. https://doi.org/10.3390/ijms23179592

Research has found that cytoplasmic HDAC6 regulates tumor proliferation, autophagy and drug resistance by modifying non-histones. Its specific inhibitors can enhance the sensitivity of chemotherapy and immunotherapy. Relevant clinical trials are underway and it is a potential target for the development of anti-cancer drugs.

4. Zhang, Qian-qian, Wei-jie Zhang, and Sheng Chang. "HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation." Frontiers in Immunology 14 (2023): 1168848. https://doi.org/10.3389/fimmu.2023.1168848

Research has found that cytoplasmic enzyme HDAC6 regulates immune responses and fibrotic pathways. Its inhibitors can alleviate ischemia-reperfusion injury after kidney transplantation, promote immune tolerance and inhibit chronic fibrosis, which is a potential new strategy for the prevention and treatment of transplantation-related complications.

5. Mondal, Prasenjit, et al. "Structure‐based discovery of a small molecule inhibitor of histone deacetylase 6 (HDAC6) that significantly reduces Alzheimer's disease neuropathology." Advanced Science 11.1 (2024): 2304545. https://doi.org/10.1002/advs.202304545

Research has found that HDAC6 is associated with Aβ deposition and tau pathology in Alzheimer's disease. The novel inhibitor PB118 significantly reduces the level of phosphorylated tau by enhancing the phagocytic clearance of Aβ by microglia, improving microtubule function and regulating inflammatory factors, demonstrating its potential as a therapeutic target for AD.

Creative Biolabs: HDAC6 Antibodies for Research

Creative Biolabs specializes in the production of high-quality HDAC6 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom HDAC6 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our HDAC6 antibodies, custom preparations, or technical support, contact us at email.